загрузка...
 
Possible application of Roncoleukin for LAK-therapy in ovarian cancer
Повернутись до змісту

Possible application of Roncoleukin for LAK-therapy in ovarian cancer

E.Y. Zlatnik, L.Y. Golotina Cancer Research Institute, Rostov-on-Don, Russia

Roncoleukin, a recombinant IL-2, was studied for the possibility of application by method of LAK-therapy. The lymph of ductus thoracicus of ovarian cancer patients receiving also autolymphochemothera- py was used as a source of lymphocytes. The immunobiologic activity of lymphocytes was studied after a 30-min incubation with Roncoleukin and also after cultivation during 24 and 48 hours. The increase of T cell proliferation, autocrine stimulation of IL-2 production, and increase of NK cell cytotoxicity were observed. A sensitizing effect of Roncoleukin on K562 target cells was shown as well: Roncoleukin increased the K562 cell sensitivity to NK-lysis. LAK-therapy with Roncoleukin-treated lymph cells was applied to ovarian cancer patients as a part of their complex treatment. The achieved effect allows considering the method to be perspective for therapy of ovarian cancer. (Cytokines and Inflammation. 2005. Vol. 4, № 2. P. 54-58.)

Key words: Roncoleukin, ovarian cancer, lymph, LAK-therapy.

 

 

 


ОРИГИНАЛЬНЫЕ СТАТЬИ

 

 

 

© Коллектив авторов, 2005

УДК 616.523-085   



загрузка...